About XTRACT Solutions

Company Overview

XTRACT Solutions combines over a decade of software development with the industry-leading outsourcing of Edge Pharma to create the only complete allergy immunotherapy management system on the market. At XTRACT we believe that safe and effective immunotherapy begins with the tools necessary to manage the entire clinic, from the time the patient walks in, through the diagnostic process, immunotherapy vial creation, and injections. A key component of this is compliance with the new USP 797 regulations for allergenic extract compounding.

Whether our customers choose to compound in-house or outsource, XTRACT has the only complete solution to ensure 797 compliance.

Meet Our Founder

XTRACT Solutions was founded in 2005 by one of the foremost authorities on immunotherapy treatment, Dr. James Baker. As a board certified allergist with over 30 years of experience treating patients with allergies, asthma, and immunological disorders, Dr. Baker recognized the need for improved tools to effectively manage the allergy clinic. XTRACT was borne out of this need, and has since evolved into the industry standard. Dr. Baker continues to see patients at his Portland, Oregon based practice, and recently was named one of Portland’s finest physicians by his colleagues.

Hear From the Professionals

“Xtract’s flexibility allowed us to implement an allergy injection and mixing software into our Children’s Hospital setting. We now have a standard operating procedure along with the peace of mind that the possibility of an injection or mixing error has been reduced to almost zero.”

“We searched for years for allergy software that would work within our Epic environment at Ochsner, and even tried to develop it ourselves. We looked at every system out there. Only Xtract could deliver the solution we needed.”

XTRACT Solutions efficiently manages all aspects of immunotherapy for both clinics and health system. Together with outsourcing from Edge Pharma, our system is the only complete solution to provide compliant immunotherapy in North America .